Acute inflammatory response to multiple chemotherapy regimen in breast carcinoma: An unreported entity¹

Article type: Case Report

Authors: Jha, Chandan Kumar^a; | Verma, Harshit^a | Sinha, Upasna^b | Singh, Prashant Kumar^a

Affiliations: [a] Department of General Surgery, All India Institute of Medical Sciences, Patna, India | [b] Department of Radiodiagnosis, All India Institute of Medical Sciences, Patna, India

Correspondence: [*] Corresponding author: Chandan Kumar Jha, MS, MCh (Endocrine Surgery), Assistant Professor (Endocrine Surgery), Department of General Surgery, All India Institute of Medical Sciences, Patna, India. Tel.: +91 9506280394; E-mail: [email protected]. ORCIDs: https://orcid.org/0000-0003-0968-3269 (C.K. Jha); https://orcid.org/0000-002-8403-013X (H. Verma); https://orcid.org/0000-0002-0915-3092 (U. Sinha); https://orcid.org/0000-0002-0999-0026 (P.K. Singh)

Note: [ 1 ] Previous presentation: This case was presented at the midterm conference of Association of Surgeons of India, Bihar Chapter in a poster form.

Abstract: Increased utilization of chemotherapy in breast cancer patients has led to improved survival outcomes but it has also resulted in rising incidence of adverse effects. Occurrence of new/unreported side effect poses challenge in front of clinicians. We report the case of a 53-year lady with locally advanced, hormone receptor-positive, and human epidermal growth factor-2 (HER-2) negative right breast carcinoma. She was started on neoadjuvant chemotherapy (NACT) (doxorubicin and cyclophosphamide), to facilitate breast-conserving surgery. She developed an inflammatory reaction involving the affected breast after each of three cycles of NACT (2 cycles of doxorubicin & cyclophosphamide, and 1 cycle of docetaxel). Infectious causes and disease progression were ruled out. She was then prescribed hormone therapy but the disease progressed after three months of therapy and the patient had to be subjected to modified radical mastectomy (MRM). She then received adjuvant radiotherapy and is currently doing well on second-line hormone therapy.

Keywords: Inflammatory response, breast carcinoma, neoadjuvant chemotherapy for breast carcinoma, inflammatory response to anthracyclines, inflammatory response to docetaxel

DOI: 10.3233/BD-220007

Journal: Breast Disease, vol. 41, no. 1, pp. 391-395, 2022